tiprankstipranks
Trending News
More News >
Biocryst Pharmaceuticals (BCRX)
NASDAQ:BCRX
US Market

BioCryst (BCRX) Stock Forecast & Price Target

Compare
2,277 Followers
See the Price Targets and Ratings of:

BCRX Analyst Ratings

Strong Buy
12Ratings
Strong Buy
11 Buy
1 Hold
0 Sell
Based on 12 analysts giving stock ratings to
BioCryst
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BCRX Stock 12 Month Forecast

Average Price Target

$16.75
▲(87.36%Upside)
Based on 12 Wall Street analysts offering 12 month price targets for BioCryst in the last 3 months. The average price target is $16.75 with a high forecast of $30.00 and a low forecast of $11.00. The average price target represents a 87.36% change from the last price of $8.94.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","10":"$10","17":"$17","24":"$24","31":"$31"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$16.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$11.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,10,17,24,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Nov<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.73,12.212307692307693,13.694615384615386,15.176923076923078,16.65923076923077,18.141538461538463,19.623846153846152,21.106153846153845,22.588461538461537,24.07076923076923,25.553076923076922,27.035384615384615,28.517692307692307,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.73,11.193076923076923,11.656153846153847,12.11923076923077,12.582307692307692,13.045384615384616,13.508461538461539,13.971538461538461,14.434615384615384,14.897692307692308,15.36076923076923,15.823846153846155,16.286923076923078,{"y":16.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.73,10.750769230769231,10.771538461538462,10.792307692307693,10.813076923076924,10.833846153846155,10.854615384615386,10.875384615384615,10.896153846153846,10.916923076923077,10.937692307692307,10.958461538461538,10.97923076923077,{"y":11,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.05,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.57,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.46,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.67,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.11,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.38,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.43,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.52,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.9,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.61,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.25,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.71,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.73,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$30.00Average Price Target$16.75Lowest Price Target$11.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on BCRX
TipRanks AITipRanks
Not Ranked
TipRanks
$9
Hold
0.67%
Upside
Reiterated
07/02/25
BioCryst faces significant financial challenges with persistent net losses and negative equity, heavily influencing its stock score. Despite positive earnings call outcomes and strategic corporate actions, the technical indicators suggest bearish momentum, and valuation metrics highlight high risk.
Wedbush
$16$18
Buy
101.34%
Upside
Reiterated
06/30/25
BioCryst price target raised to $18 from $16 at WedbushBioCryst price target raised to $18 from $16 at Wedbush
Bank of America Securities Analyst forecast on BCRX
Tazeen AhmadBank of America Securities
Bank of America Securities
$13$15
Buy
67.79%
Upside
Reiterated
06/30/25
BioCryst's Strategic Sale and Debt Retirement Strengthen Financial Position and Justify Buy Rating
Needham
$17
Buy
90.16%
Upside
Reiterated
06/27/25
Needham Sticks to Its Buy Rating for BioCryst (BCRX)
RBC Capital Analyst forecast on BCRX
Brian AbrahamsRBC Capital
RBC Capital
$13
Buy
45.41%
Upside
Reiterated
06/27/25
Analysts Are Bullish on These Healthcare Stocks: Chemed (CHE), Altimmune (ALT)
Barclays Analyst forecast on BCRX
Gena WangBarclays
Barclays
$8$11
Hold
23.04%
Upside
Reiterated
05/07/25
Barclays Sticks to Its Hold Rating for BioCryst (BCRX)
Evercore ISI Analyst forecast on BCRX
Liisa BaykoEvercore ISI
Evercore ISI
$12
Buy
34.23%
Upside
Reiterated
05/06/25
Evercore ISI Keeps Their Buy Rating on BioCryst (BCRX)
J.P. Morgan Analyst forecast on BCRX
Jessica FyeJ.P. Morgan
J.P. Morgan
$10$13
Buy
45.41%
Upside
Reiterated
05/06/25
J.P. Morgan Remains a Buy on BioCryst (BCRX)
H.C. Wainwright Analyst forecast on BCRX
Andrew FeinH.C. Wainwright
H.C. Wainwright
$30
Buy
235.57%
Upside
Reiterated
05/06/25
H.C. Wainwright Keeps Their Buy Rating on BioCryst (BCRX)
Jefferies
$12$14
Buy
56.60%
Upside
Reiterated
05/05/25
BioCryst Pharma (BCRX) PT Raised to $14 at JefferiesJefferies analyst Maury Raycroft raised the price target on BioCryst Pharma (NASDAQ: BCRX) to $14.00 (from $12.00) while maintaining a Buy rating.
TD Cowen Analyst forecast on BCRX
Stacy KuTD Cowen
TD Cowen
$20
Buy
123.71%
Upside
Reiterated
05/05/25
BioCryst's Orladeyo Surpasses Expectations: A Strong Buy Recommendation
Cantor Fitzgerald Analyst forecast on BCRX
Steven SeedhouseCantor Fitzgerald
Cantor Fitzgerald
$20
Buy
123.71%
Upside
Initiated
04/28/25
BioCryst initiated with an Overweight at Cantor FitzgeraldBioCryst initiated with an Overweight at Cantor Fitzgerald
Citizens JMP Analyst forecast on BCRX
Jonathan WollebenCitizens JMP
Citizens JMP
$18
Buy
101.34%
Upside
Reiterated
04/23/25
Citizens JMP reiterates Market Outperform Rating on BioCryst Pharma (BCRX)Citizens JMP analyst Jonathan Wolleben reiterated a Market Outperform rating and $18.00 price target on BioCryst Pharma (NASDAQ: BCRX).
Piper Sandler Analyst forecast on BCRX
Christopher RaymondPiper Sandler
Piper Sandler
$20
Buy
123.71%
Upside
Assigned
10/23/24
Piper Sandler Sticks to Its Buy Rating for BioCryst (BCRX)
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on BCRX
TipRanks AITipRanks
Not Ranked
TipRanks
$9
Hold
0.67%
Upside
Reiterated
07/02/25
BioCryst faces significant financial challenges with persistent net losses and negative equity, heavily influencing its stock score. Despite positive earnings call outcomes and strategic corporate actions, the technical indicators suggest bearish momentum, and valuation metrics highlight high risk.
Wedbush
$16$18
Buy
101.34%
Upside
Reiterated
06/30/25
BioCryst price target raised to $18 from $16 at WedbushBioCryst price target raised to $18 from $16 at Wedbush
Bank of America Securities Analyst forecast on BCRX
Tazeen AhmadBank of America Securities
Bank of America Securities
$13$15
Buy
67.79%
Upside
Reiterated
06/30/25
BioCryst's Strategic Sale and Debt Retirement Strengthen Financial Position and Justify Buy Rating
Needham
$17
Buy
90.16%
Upside
Reiterated
06/27/25
Needham Sticks to Its Buy Rating for BioCryst (BCRX)
RBC Capital Analyst forecast on BCRX
Brian AbrahamsRBC Capital
RBC Capital
$13
Buy
45.41%
Upside
Reiterated
06/27/25
Analysts Are Bullish on These Healthcare Stocks: Chemed (CHE), Altimmune (ALT)
Barclays Analyst forecast on BCRX
Gena WangBarclays
Barclays
$8$11
Hold
23.04%
Upside
Reiterated
05/07/25
Barclays Sticks to Its Hold Rating for BioCryst (BCRX)
Evercore ISI Analyst forecast on BCRX
Liisa BaykoEvercore ISI
Evercore ISI
$12
Buy
34.23%
Upside
Reiterated
05/06/25
Evercore ISI Keeps Their Buy Rating on BioCryst (BCRX)
J.P. Morgan Analyst forecast on BCRX
Jessica FyeJ.P. Morgan
J.P. Morgan
$10$13
Buy
45.41%
Upside
Reiterated
05/06/25
J.P. Morgan Remains a Buy on BioCryst (BCRX)
H.C. Wainwright Analyst forecast on BCRX
Andrew FeinH.C. Wainwright
H.C. Wainwright
$30
Buy
235.57%
Upside
Reiterated
05/06/25
H.C. Wainwright Keeps Their Buy Rating on BioCryst (BCRX)
Jefferies
$12$14
Buy
56.60%
Upside
Reiterated
05/05/25
BioCryst Pharma (BCRX) PT Raised to $14 at JefferiesJefferies analyst Maury Raycroft raised the price target on BioCryst Pharma (NASDAQ: BCRX) to $14.00 (from $12.00) while maintaining a Buy rating.
TD Cowen Analyst forecast on BCRX
Stacy KuTD Cowen
TD Cowen
$20
Buy
123.71%
Upside
Reiterated
05/05/25
BioCryst's Orladeyo Surpasses Expectations: A Strong Buy Recommendation
Cantor Fitzgerald Analyst forecast on BCRX
Steven SeedhouseCantor Fitzgerald
Cantor Fitzgerald
$20
Buy
123.71%
Upside
Initiated
04/28/25
BioCryst initiated with an Overweight at Cantor FitzgeraldBioCryst initiated with an Overweight at Cantor Fitzgerald
Citizens JMP Analyst forecast on BCRX
Jonathan WollebenCitizens JMP
Citizens JMP
$18
Buy
101.34%
Upside
Reiterated
04/23/25
Citizens JMP reiterates Market Outperform Rating on BioCryst Pharma (BCRX)Citizens JMP analyst Jonathan Wolleben reiterated a Market Outperform rating and $18.00 price target on BioCryst Pharma (NASDAQ: BCRX).
Piper Sandler Analyst forecast on BCRX
Christopher RaymondPiper Sandler
Piper Sandler
$20
Buy
123.71%
Upside
Assigned
10/23/24
Piper Sandler Sticks to Its Buy Rating for BioCryst (BCRX)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BioCryst

1 Month
xxx
Success Rate
15/23 ratings generated profit
65%
Average Return
+7.83%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 65.22% of your transactions generating a profit, with an average return of +7.83% per trade.
3 Months
xxx
Success Rate
8/15 ratings generated profit
53%
Average Return
+7.34%
reiterated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 53.33% of your transactions generating a profit, with an average return of +7.34% per trade.
1 Year
Brian AbrahamsRBC Capital
Success Rate
13/15 ratings generated profit
87%
Average Return
+25.17%
reiterated a buy rating 10 days ago
Copying Brian Abrahams's trades and holding each position for 1 Year would result in 86.67% of your transactions generating a profit, with an average return of +25.17% per trade.
2 Years
xxx
Success Rate
13/15 ratings generated profit
87%
Average Return
+31.51%
reiterated a xxx
rating 10 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 86.67% of your transactions generating a profit, with an average return of +31.51% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BCRX Analyst Recommendation Trends

Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
13
11
12
10
12
Buy
13
8
6
6
7
Hold
2
1
1
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
28
20
19
17
20
In the current month, BCRX has received 19 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. BCRX average Analyst price target in the past 3 months is 16.75.
Each month's total comprises the sum of three months' worth of ratings.

BCRX Financial Forecast

BCRX Earnings Forecast

Next quarter’s earnings estimate for BCRX is <$0.01 with a range of -$0.01 to $0.03. The previous quarter’s EPS was $0.00. BCRX beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.09% of the time in the same period. In the last calendar year BCRX has Outperformed its overall industry.
Next quarter’s earnings estimate for BCRX is <$0.01 with a range of -$0.01 to $0.03. The previous quarter’s EPS was $0.00. BCRX beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.09% of the time in the same period. In the last calendar year BCRX has Outperformed its overall industry.

BCRX Sales Forecast

Next quarter’s sales forecast for BCRX is $149.22M with a range of $143.07M to $156.03M. The previous quarter’s sales results were $145.53M. BCRX beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.49% of the time in the same period. In the last calendar year BCRX has Outperformed its overall industry.
Next quarter’s sales forecast for BCRX is $149.22M with a range of $143.07M to $156.03M. The previous quarter’s sales results were $145.53M. BCRX beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.49% of the time in the same period. In the last calendar year BCRX has Outperformed its overall industry.

BCRX Stock Forecast FAQ

What is BCRX’s average 12-month price target, according to analysts?
Based on analyst ratings, Biocryst Pharmaceuticals’s 12-month average price target is 16.75.
    What is BCRX’s upside potential, based on the analysts’ average price target?
    Biocryst Pharmaceuticals has 87.36% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BCRX a Buy, Sell or Hold?
          Biocryst Pharmaceuticals has a consensus rating of Strong Buy which is based on 11 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Biocryst Pharmaceuticals’s price target?
            The average price target for Biocryst Pharmaceuticals is 16.75. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $30.00 ,the lowest forecast is $11.00. The average price target represents 87.36% Increase from the current price of $8.94.
              What do analysts say about Biocryst Pharmaceuticals?
              Biocryst Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of BCRX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis